PGC-01
PGC-01 is a PROTAC degrader targeting GSDMD, with a DC50 of 3.32 μM in THP-1 cells. PGC-01 mediates CRBN-dependent ubiquitination and proteasomal degradation of full-length GSDMD, blocking pyroptosis at the source. PGC-01 concentration-dependently inhibits Nigericin (HY-127019)-induced macrophage pore formation, cell death, and IL-1β release. PGC-01 can be used for colitis research.
(Pink: GSDMD ligand (HY-189672); Blue: Cereblon ligand (HY-W087383); Black: linker (HY-42773)).
For research use only. We do not sell to patients.
- Formula: C47H49F2N7O7
- Molecular Weight:861.93
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
GSDMD 3.32 μM (DC50) |
In Vitro
PGC-01 (0.31-20 μM; 1-48 h) degrades GSDMD in THP-1 cells with a DC50 of 3.32 μM and a Dmax of 85%[1].
PGC-01 (10 μM; 8 h)-induced GSDMD degradation in THP-1 cells requires CRBN binding and a functional ubiquitin-proteasome pathway[1].
PGC-01 (5-10 μM; 8 h) inhibits Nigericin (HY-127019)-induced pyroptosis in THP-1 macrophages and suppresses IL-1β release, with an IC50 of 3.22 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:THP-1 cells
-
Concentration:1, 10, 20 μM (GSDMD degradation screening); 10 μM (time course); 0.31, 0.62, 1.25, 2.5, 5, 10, 20 μM (dose-response at 12 h)
-
Incubation Time:1, 2, 4, 8, 12, 24, 48 h (10 μM time course); 12 h (dose-response)
-
Result:Degraded GSDMD by 23% at 1 μM, 85% at 10 μM, and 83% at 20 μM.
At 10 μM, GSDMD decreased rapidly to approximately 85% degradation within 8 h, and this degradation was sustained up to 12 h or longer.
In the 12-h dose-response experiment, DC50 = 3.32 μM and Dmax = 85%.
-
Cell Line:THP-1 cells
-
Concentration:10 μM
-
Incubation Time:8 h
-
Result:Co-incubation with Thalidomide (HY-14658) blocked PGC-01-mediated GSDMD degradation.
GSDMD protein levels were restored upon co-incubation with MG132 (HY-13259) or Carfilzomib (HY-10455).
Parmacokinetics
| Species | Dose | Route | Cmax | T1/2α | T1/2β | AUC | CL | MRT | Vss | V1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 2 mg/kg | i.v. | 143.5 ng/mL | 10.40 min | 283.50 min | 5691 min·ng/mL | 363.31 mL/min/kg | 285.86 min | 103.33 L/kg | 16.36 L/kg |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male; weight 20-22 g; age 6-8 weeks)[1]
-
Dosage:2 mg/kg; 10 mg/kg
-
Administration:rectal; daily; for 7 days
-
Result:10 mg/kg PGC-01 significantly ameliorated body weight loss, diarrhea, rectal bleeding, colon shortening, and increased spleen weight index.
This dose also mitigated endoscopic mucosal damage, histopathological abnormalities, and intestinal epithelial cell loss.
The 2 mg/kg dose also significantly alleviated these symptoms, but its effects were milder than those of the 10 mg/kg dose.
Chemical Information
-
Molecular Weight 861.93
-
Formula C47H49F2N7O7
-
SMILES
O=C(C1=CC=C(C=C1)C(NC2=CC=C(C=C2)N3CCN(CC3)C(CC4=C(C=C(C=C4)F)F)=O)=O)NCCCCCCCCNC5=CC=C6C(N(C(C6=C5)=O)C7CCC(NC7=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)